Role of Transrectal Ultrasonography in Prostate Cancer

Radiologic Clinics of North America

Volumn 50, Issue 6, 2012, Pages 1061-1073

  Ghai, Sangeet ^a,b   Toi, Ants ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Prostate cancer; Screening; Targeted biopsy; Transrectal ultrasound

Indexed keywords

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER SCREENING; CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; ELASTOGRAPHY; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; CONTRAST MEDIA; ELASTICITY IMAGING TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATE; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84868294320     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2012.08.007     Document Type: Review

References (88)

1. Watanabe H., Igari D., Tanahasi Y., et al. Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound 1974, 2:91-98.
2. Watanabe H. History and applications of transrectal sonography of the prostate. Urol Clin North Am 1989, 16:617-622.
3. Canadian cancer society. Statistics for 2011. Available at: Accessed August 29, 2012. http://www.cancer.ca.
4. Levy I.G., Iscoe N.A., Klotz L.H. Prostate cancer. 1. The descriptive epidemiology in Canada. CMAJ 1998, 159:509-513.
5. Neal D.E., Leung H.Y., Powell P.H., et al. Unanswered questions in screening for prostate cancer. Eur J Cancer 2000, 36:1316-1321.
6. Rietbergen J.B., Schroder F.H. Screening for prostate cancer: more questions than answers. Acta Oncol 1998, 37:515-532.
7. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002, 168:906-913.
8. Sexton W.J., Spiess P.E., Pisters L.L., et al. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. Int Braz J Urol 2010, 36(5):571-582.
9. Che M., Sakr W., Grignon D. Pathologic features the urologist should expect on a prostate biopsy. Urol Oncol 2003, 21:153-161.
10. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
11. Epstein J.I., Allsbrook W.C., Amin M.B., et al. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006, 13:57-59.
12. Nam R.K., Jewett M.A., Krahn M.D. Prostate cancer. 2. Natural history. CMAJ 1998, 159:685-691.
13. Campbell-Walsh urology 2007, Saunders, Philadelphia. 9th edition. M.F. Campbell, A.J. Wein, L.R. Kavoussi (Eds.).
14. Shao Y.H., Demissie K., Shih W., et al. Contemporary risk profile of prostate cancer in the US. J Natl Cancer Inst 2009, 101:1280-1283.
15. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
16. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
17. Eckersberger E., Finkelstein J., Sadri H., et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol 2009, 11(3):127-133.
18. Schröder F.H., Roobol M.J. ERSPC and PLCO prostate cancer screening studies: what are the differences?. Eur Urol 2010, 58(1):46-52.
19. Bunting P.S., DeBoer G., Choo R., et al. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002, 35:471-475.
20. Polascik T.J., Oesterling J.E., Partin A.W. Prostate-specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999, 162:293-306.
21. Alapont Alacreu J.M., Navarro Rosales S., Budia Alba A., et al. Actas Urol Esp 2008, 32:575-588. [in Spanish].
22. Jung K., Meyer A., Lein M., et al. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 1998, 159:1595-1598.
23. Gonzalgo M.L., Carter H.B. Update on PSA testing. J Natl Compr Canc Netw 2007, 5:737-742.
24. Thompson I.M., Ankerst D.P. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007, 176:1853-1858.
25. Toi A., Neill M.G., Lockwood G.A., et al. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007, 177:516-520.
26. Loeb S., Catalona W.J. What to do with an abnormal PSA test. Oncologist 2008, 13:299-305.
27. Littrup P.J., Bailey S.E. Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am 2000, 38:87-113.
28. Lee F., Gray J.M., McLeary R.D., et al. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 1985, 7:117-129.
29. Toi A. The prostate. Diagnostic ultrasound 2011, 392-428. Elsevier, Philadelphia. C.M. Rumack, S.R. Wilson, W.J. Carboneau (Eds.).
30. Shinohara K., Scardino P.T., Carter S.S., et al. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am 1989, 16:675-691.
31. Shinohara K., Wheeler T.M., Scardino P.T. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 1989, 142:76-82.
32. Dyke C.H., Toi A., Sweet J.M. Value of random ultrasound-guided transrectal prostate biopsy. Radiology 1990, 176:345-349.
33. Dahnert W.F., Hamper U.M., Walsh P.C., et al. The echogenic focus in prostatic sonograms, with xeroradiographic and histopathologic correlation. Radiology 1986, 159:95-100.
34. Rifkin M.D., Dahnert W., Kurtz A.B. State of the art: endorectal sonography of the prostate gland. AJR Am J Roentgenol 1990, 154:691-700.
35. Hamper U.M., Sheth S., Walsh P.C., et al. Bright echogenic foci in early prostatic carcinoma: sonographic and pathologic correlation. Radiology 1990, 176:339-343.
36. Lawrentschuk N., Haider M.A., Daljeet N., et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int 2010, 105:1231-1236.
37. Amiel G.E., Slawin K.M. Newer modalities of ultrasound imaging and treatment of the prostate. Urol Clin North Am 2006, 33:329-337.
38. Wijkstra H., Wink M.H., de la Rosette J.J. Contrast-specific imaging in the detection and localization of prostate cancer. World J Urol 2004, 22:346-350.
39. Pallwein L., Mitterberger M., Pelzer A., et al. Ultrasound of prostate cancer: recent advances. Eur Radiol 2008, 18:707-715.
40. Halpern E.J., Ramey J.R., Strup S.E., et al. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005, 104(11):2373-2383.
41. Taverna G., Morandi G., Seveso M., et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int 2011, 108:1723-1727.
42. Bree R.L. The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997, 49(Suppl 3A):31-34.
43. Pelzer A., Bektic J., Berger A.P., et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005, 173(6):1926-1929.
44. Roy C., Buy X., Lang H., et al. Contrast enhanced color Doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedure. J Urol 2003, 170(1):69-72.
45. Mitterberger M., Pinggera G., Horninger W., et al. Comparison of contrast enhanced colour Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 2007, 178(2):464-468.
46. Mitterberger M., Pinggera G., Horninger W., et al. Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol 2008, 53(1):112-117.
47. Halpern E.J., McCue P.A., Aksnes A.K., et al. Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients. Radiology 2002, 222:361-366.
48. Halpern E.J., Frauscher F., Rosenberg M., et al. Directed biopsy during contrast-enhanced sonography of the prostate. AJR Am J Roentgenol 2002, 178(4):915-919.
49. Pallwein L., Mitterberger M., Struve P., et al. Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int 2007, 100(1):42-46.
50. Konig K., Scheipers U., Pesavento A., et al. Initial experiences with real-time elastography guided biopsies of the prostate. J Urol 2005, 174(1):115-157.
51. Pallwein L., Mitterberger M., Struve P., et al. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol 2007, 17(9):2278-2285.
52. El-Hakim A., Moussa S. CUA guidelines on prostate biopsy methodology. Can Urol Assoc J 2010, 4(2):89-94.
53. Tal R., Livne P.M., Lask D.M., et al. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003, 169:1762-1765.
54. Shigehara K., Miyagi T., Nakashima T., et al. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother 2008, 14:40-43.
55. Maan Z., Cutting C.W., Patel U., et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int 2003, 91:798-800.
56. Rodriguez L.V., Terris M.K. Risks and complications of transrectal ultrasound-guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998, 160:2115-2120.
57. Herget E.J., Saliken J.C., Donnelly B.J., et al. Transrectal ultrasound-guided biopsy of the prostate: relation between ASA use and bleeding complications. Can Assoc Radiol J 1999, 50:173-176.
58. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997, 336:1506-1511.
59. Nash P.A., Bruce J.E., Indudhara R., et al. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996, 155:607-609.
60. Ching C.B., Moussa A.S., Li J., et al. Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates. J Urol 2009, 181:2077-2082.
61. Dominguez-Escrig J.L., McCracken S.R., Greene D. Beyond diagnosis: evolving prostate biopsy in the era of focal therapy. Prostate Cancer 2011, 2011:386207.
62. Shariat S.F., Roehrborn C.G. Using biopsy to detect prostate cancer. Rev Urol 2008, 10:262-280.
63. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997, 157:199-202.
64. Singh H., Canto E.I., Shariat S.F., et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 2004, 171:1850-1854.
65. Taneja S.S., Mason M. Candidate selection for prostate cancer focal therapy. J Endourol 2010, 24:835-841.
66. Scales C.D., Presti J.C., Kane C.J., et al. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy-results from the SEARCH database. J Urol 2007, 178:1249-1252.
67. Tsivian M., Kimura M., Sun L., et al. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2010, 105:1089-1092.
68. Walz J., Graefen M., Chun F.K., et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006, 50:498-505.
69. Stewart C.S., Leibovich B.C., Weaver A.L., et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001, 166:86-91.
70. Ashley R.A., Inman B.A., Routh J.C., et al. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol 2008, 53:976-981.
71. Pepe P., Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007, 70:1131-1135.
72. Falzarano S.M., Zhou M., Hernandez A.V., et al. Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology 2010, 76:682-687.
73. Heijmink S.W., van Moerkerk H., Kiemeney L.A., et al. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol 2006, 16:927-938.
74. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
75. Keetch D.W., Catalona W.J., Smith D.S. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994, 151:1571-1574.
76. Djavan B., Ravery V., Zlotta A., et al. Prospective evaluation of prostate cancer detection on biopsies 1, 2, 3, 4: when should we stop?. J Urol 2001, 166:1679-1683.
77. Tanimoto A., Nakashima J., Kohno H., et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007, 25:146-152.
78. Sciarra A., Barentsz J., Bjartell A., et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011, 59:962-977.
79. Hoeks C.M., Schouten M.G., Bomers J.G., et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012, [Epub ahead of print].
80. Engelhard K., Hollenbach H.P., Kiefer B., et al. Prostate biopsy in the supine position in a standard 1.5T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006, 16:1237-1243.
81. Hambrock T., Diederik S.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010, 183:520-527.
82. Anastasiadis A.G., Lichy M.P., Nagele U., et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006, 50:738-748.
83. Lee S.H., Chung M.S., Chung B.H. Magnetic resonance imaging targeted biopsy in men with previously negative prostate biopsies. J Endourol 2012, 26(7):787-791.
84. Littrup P.J. Imaging and prostate cancer chemoprevention: current diagnosis and future directions. Urology 2001, 57:121-123.
85. Arsov C., Quentin M., Rabenalt R., et al. Repeat transrectal ultrasound guided biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA-a pilot study. Anticancer Res 2012, 32:1087-1092.
86. Kaplan I., Oldenburg N.E., Meskell P., et al. Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging 2002, 20:295-299.
87. Xu S., Kruecker J., Turkbey B., et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008, 13:255-264.
88. Pinto P.A., Chung P.H., Rastinehad A.R., et al. Magnetic resonance imaging/ultrasound fusion guided biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011, 186:1281-1285.